NEW HOPE FERTILITY DIVISION OF FERTILITY PRESERVATION
New Hope Fertility in NYC is dedicated to providing the best, cutting-edge, and reliable fertility preservation solutions. As one of the first American centers to offer this process, Dr. John Zhang pioneered egg freezing with vitrification and has had over 400 live births from frozen embryos.
To continue offering the best fertility preservation possible, Dr. John Zhang has partnered with the Director and Founder of FertilityPreservation.org, Dr. Kutluk Oktay. A leader in onco-fertility, Dr. Oktay is one of the world’s leading experts in ovarian tissue freezing, ovarian transplants, as well as ovarian stimulation in breast cancer patients. He is also an expert in fertility preservation in children including those facing cancer and Turner Syndrome. Together we bring you the New Hope Division of Fertility Preservation.
Whether your desire is to delay your fertility until you are ready to start a family or to preserve your fertility in preparation of chemotherapy or other treatments that may threaten the future of your fertility, our Division of Fertility Preservation offers a full-range of options for you:
- Ovarian Tissue Freezing and Transplantation
- In Vitro Maturation
- Infertility Treatments after Chemotherapy
- Post-mortem Emergency Fertility Preservation
- Medically Indicated Oocyte Freezing
- Fertility Preservation in Children
- Random Start Ovarian Stimulation
- Pregnancy after Cancer
With over a decade of experience, we are the recommended source for fertility preservation of professionals. There is no better time to start freezing than right now!
Call to schedule your first consultation today:
DR. KUTLUK OKTAY
Director of the Division of Fertility Preservation
Kutluk Oktay, MD, PhD, FACOG is Professor of Obstetrics & Gynecology, Medicine, Pathology, and Cell Biology & Anatomy, Director, Division of Reproductive Medicine & Institute for Fertility Preservation at New York Medical College (NYMC). Dr. Oktay completed his residency in Obstetrics and Gynecology at the University of Connecticut Health Science Center in Farmington, CT, followed by a fellowship in Reproductive Endocrinology and Infertility at the University of Texas Health Science Center at San Antonio, TX. He was subsequently awarded to be an American College of OBGYN (ACOG)/Royal College of OBGYN (RCOG) Exchange Fellow in the Department of Reproductive Biology, Obstetrics & Gynecology at Leeds University School of Medicine/Leeds General Infirmary in the UK. Dr. Oktay subsequently obtained a Doctor of Health Sciences degree (PhD) from the University of Ghent, Belgium.
Dr. Oktay’s professional life has been dedicated to the science of fertility preservation and infertility treatments. As a clinician-scientist, he is a leading expert in fertility preservation, as well as in ovarian stimulation and in vitro fertilization. He developed and performed the world’s first ovarian transplantation procedures and pioneered new ovarian stimulation protocols for embryo and oocyte freezing for breast and endometrial cancer patients. In addition, he described the first oocyte freezing protocols in young pubertal girls with Turner syndrome and other medical conditions. He has championed fertility preservation in children of all ages. Dr. Oktay recently developed a new ovarian transplantation technique utilizing a human extracellular matrix scaffold and robotic surgery, which resulted in the first livebirths with this technique and promises to improve the outcomes of ovarian transplantation. Dr. Oktay conducted key research on ovarian follicle and embryo development, as well as on controlled ovarian stimulation and in vitro fertilization. Following his first description of the relationship between BRCA mutations and low ovarian reserve, his work led him to discover a key role for DNA repair efficiency in oocyte aging.
Dr. Oktay was invited to serve on the President’s Cancer Panel’s advisory board as an expert on fertility issues of cancer patients and fertility preservation. In attestation to his recognition as a leading clinician-scientist in infertility field, he has been continuously funded by the National Institutes of Health to study various aspects of ovarian biology and fertility preservation. Furthermore, he serves as the Co-chair of the American Society of Clinical Oncology Committee for Fertility Preservation Guideline for People with Cancer since 2005. Dr. Oktay founded and was elected as the first President of the Fertility Preservation Special Interest Group at American Society of Reproductive Medicine, the largest within the society. He also served as the Guidelines Committee Chair at Turner Syndrome Foundation, which produced the first guidelines document on fertility preservation for young females with Turner Syndrome.
Dr. Oktay received many prestigious awards both from professional and patient organizations. He was named among the top Doctors in America by Castle and Connolly numerous times, received innovator award from Resolve, and the Champions of Hope award from Fertile Hope. He has been invited to endowed lectures in top standing institutions and major academic conferences in the US and around the world in infertility, cancer, pediatric endocrinology, obstetrics & gynecology, genetics, aging, and other fields.
In 2008, after a 10 year career at the Weill Medical College of Cornell University, Dr. Oktay transitioned to NYMC, and subsequently founded the Innovation Institute for Fertility Preservation and IVF (IFP). In addition to his roles at NYMC as Professor of Obstetrics & Gynecology and Director of Division of Reproductive Medicine & Infertility, Dr. Oktay is also the Vice Chair of Research in the Department of Obstetrics & Gynecology at NYMC, and has also served a consultant physician at Memorial Sloan-Kettering Cancer Center and Consultant for Cancer and Allied Diseases at Memorial Hospital and currently continues his active collaborations with renown cancer specialists at MSKCC.
A significant contributor to the peer-reviewed literature, Dr. Oktay has published extensively in leading medical journals, such as the New England Journal of Medicine, Lancet, Science Translational Medicine, JAMA, JAMA Oncology, and Journal of Clinical Oncology.